Payment overview · 2025
General Payments
$141.52
8 reported records · 6 companies
Healthcare provider profile · identity verified
Peter N. Katsaros, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NORTON, OH · NPI 1144203910
Verified facts
What the public records show
CMS Open Payments records show Peter N. Katsaros, M.D. received $141.52 in general payments during 2025 across 8 reported records.
Amgen Inc. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Otezla, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 336 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.13 | 21.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.10 | 21.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.55 | 20.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.50 | 15.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.32 | 11.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.92 | 9.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.52 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
336 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 756 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 710 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 520 | 103 |
| Furosemide | Furosemide | 362 | 50 |
| Lisinopril | Lisinopril | 344 | 58 |
| Eliquis | Apixaban | 336 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 331 | 62 |
| Omeprazole | Omeprazole | 329 | 75 |
| Gabapentin | Gabapentin | 303 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 52 |
| Metformin Hcl | Metformin Hcl | 270 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 48 |
| Potassium Chloride | Potassium Chloride | 236 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 40 |
| Carvedilol | Carvedilol | 202 | 30 |
| Donepezil Hcl | Donepezil Hcl | 200 | 27 |
| Losartan Potassium | Losartan Potassium | 194 | 40 |
| Prednisone | Prednisone | 194 | 79 |
| Sertraline Hcl | Sertraline Hcl | 189 | 39 |
| Azithromycin | Azithromycin | 187 | 103 |
| Quetiapine Fumarate | Quetiapine Fumarate | 181 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 23 |
| Glimepiride | Glimepiride | 147 | 26 |
| Mirtazapine | Mirtazapine | 144 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 35 |
| Trazodone Hcl | Trazodone Hcl | 135 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 28 |
| Simvastatin | Simvastatin | 116 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 26 |
| Memantine Hcl | Memantine Hcl | 109 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 51 |
| Buspirone Hcl | Buspirone Hcl | 105 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 18 |
| Warfarin Sodium | Warfarin Sodium | 90 | suppressed |
| Famotidine | Famotidine | 86 | 19 |
| Meloxicam | Meloxicam | 82 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 31 |
| Pregabalin | Pregabalin | 75 | 11 |
| Spironolactone | Spironolactone | 74 | 16 |
| Allopurinol | Allopurinol | 71 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 71 | 19 |
| Tradjenta | Linagliptin | 69 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 41 |
| Divalproex Sodium | Divalproex Sodium | 67 | suppressed |
| Myrbetriq | Mirabegron | 66 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 44 |
| Clonidine Hcl | Clonidine Hcl | 65 | 14 |
| Latanoprost | Latanoprost | 65 | 12 |
| Torsemide | Torsemide | 62 | 13 |
| Tramadol Hcl | Tramadol Hcl | 62 | 15 |
| Alendronate Sodium | Alendronate Sodium | 61 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 61 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 11 |
| Finasteride | Finasteride | 59 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 54 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 13 |
| Amoxicillin | Amoxicillin | 51 | 27 |
| Benazepril Hcl | Benazepril Hcl | 51 | 15 |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 24 |
| Sucralfate | Sucralfate | 48 | 13 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 11 |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 11 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Zaleplon | Zaleplon | 41 | 11 |
| Cefuroxime | Cefuroxime Axetil | 40 | 29 |
| Ibuprofen | Ibuprofen | 40 | 13 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 32 | 32 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Cephalexin | Cephalexin | 30 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 11 |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Corlanor | Ivabradine Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 19 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 11 |
| Lactulose | Lactulose | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 12 |
| Trospium Chloride | Trospium Chloride | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Ertapenem | Ertapenem Sodium | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 14 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Ethosuximide | Ethosuximide | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.52 · 8 records | Amgen Inc. | Auvelity, CAPVAXIVE, FREESTYLE LIBRE 2, GARDASIL 9, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, VAXNEUVANCE, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Otezla play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error